LRYGB had the greatest lifetime costs at every age ($13,506 vs. no treatment, $3,859 vs. LAGB), but also the greatest amount of QALYs gained (2.54 more vs. no treatment, 1.32 vs. LAGB), leading to a lower ICER than LAGB when compared with no treatment ($5,324 and $7943/QALY, respectively). When LRYGB was compared to LAGB, a relatively low ICER of $2,918/QALY resulted at age 40. ICERs in both comparisons increased steadily with age. In one-way sensitivity analyses for LRYGB against no treatment, the most sensitive parameters were medical costs associated with initial baseline BMI (ICER varied ϳ187%), and medical costs associated with LRYGB efficacy (ϳ80%). The results of LAGB against no treatment were similar, although utility associated with efficacy was much more sensitive in comparison. In results for LRYGB versus LAGB, the model was most sensitive to recurring medical cost parameters associated with efficacy of treatment. CONCLUSIONS: Both LRYGB and LAGB were found to be cost-effective compared to no treatment for morbidly obese people, with ICERs below $25,000 up to age sixty. These results were robust to reasonable model parameter changes. This study also suggests that LRYGB may be more costeffective than LAGB due to the relative improvement in QALYs gained. 
OBJECTIVES:
To evaluate the cost-effectiveness of bariatric surgery in obese Korean people. METHODS: The target population was obesity patients defined as having a body mass index (BMI) of BMIՆ30kg/m2 with diabetes. This study performed in Healthcare system perspectives. The bariatric surgery comprised laparoscopic adjustable gastric banding (LAGB), Roux-en Y gastric bypass (RYGB), and Sleeve gastrectomy (SG). The comparison, non-surgical treatments consisted of physician visit, exercise, diet, and pharmacotherapy. For cost-effectiveness analysis, the decision model with a one year time horizon was used. The effectiveness associated with percent weight change from baseline, BMI reduction, and proportion of patients with more than 10% weight change. The cost data was collected from the survey of 9 medical centers who had conducted these obesity treatments and Korean national health insurance statistics, based on 2011 costs. The effectiveness data and distribution of surgery and complication was collected from 7 multicenter, 485 patients retrospective chart review. Incremental cost-effectiveness ratio (ICER) of bariatric surgery compared to non-surgery interventions was calculated in obese people. Subgroup analysis using various BMI level with/without diabetes and probability sensitivity analysis were conducted to assess the stability of base-case results. RESULTS: The bariatric surgery had higher cost (US$9273) and better effectiveness(18.1% weight loss), the Incremental cost-effectiveness ratio (ICER) was US$512 per one-percent weight loss. Through the subgroup and sensitivity analysis under various conditions, robustness of the study results was also demonstrated. CONCLUSIONS: The cost-effectiveness study for clinical outcomes indicated that bariatric surgery was clinical and cost effective alternative to conventional therapy in obese patients. 
PSU26

COST-UTILITY ANALYSIS OF BARIATRIC SURGERY FOR THE TREATMENT OF OBESE PATIENTS IN SOUTH KOREA
OBJECTIVES:
The purpose of this study was to assess the cost-utility of bariatric surgery compared to non-surgical interventions in obese Korean people. METHODS: We used Markov model comparing the lifetime expected costs and quality adjusted life years (QALY) between bariatric surgery and non-surgery intervention from Korean Healthcare system perspectives. Our target cohort consisted of obese people defined as having a body mass index (BMI) of 30-40 in South Korea. The starting age of cohort was 30 years old. The non-surgical interventions include physician visit, exercise, diet, and pharmacotherapy. The cycle length was 1 year and used half-cycle correction. The health status comprised five states such as no comorbidity, mild/moderate comorbidity (diabetes or/and hypertension or/ and, dyslipidemia), severe comorbidity (CHD or/and stroke), death due to CVD, and death due to other cause. Input data of transition probability for each disease status and utility weight calculated from the relationship between weight loss and QALY gain using Korean National Health and Nutrition Examination Survey data. The rate of death due to CVD and other cause were calculated Korean death statistics. The cost data was collected from the survey of 9 medical center who had conducted those obesity treatments and Korean national health insurance statistics, based on 2011 costs. Discount of 5% was applied in cost and QALY. Incremental cost-effectiveness ratio (ICER) of bariatric surgery compared to non-surgery interventions was calculated. RESULTS: The cost-utility study indicated that bariatric surgery had US$1,522 Incremental costs and 0.86 Incremental QALY compared non-surgical interventions. Through the base case analysis, ICER was US$1771/QALY. The sensitivity analyses under a variety of assumption, robustness of the study results were also demonstrated. CONCLUSIONS: The study indicated that bariatric surgery was cost-effective alternative to non-surgical interventions over lifetime, providing substantial lifetime benefits in obese Korean people. OBJECTIVES: To assess differences in demographics, comorbidities, and healthcare costs and utilization among patients undergoing total hip replacement (THR) surgery with and without muscle atrophy/weakness (MAW). METHODS: Using large US administrative claims databases, we examined individuals aged 50ϩ with commercial insurance or Medicare supplemental insurance who were hospitalized for THR between January 2006 to September 30, 2009. The first hospitalization was defined as the index stay. Three cohorts were further identified based on whether individuals had medical claims associated with MAW over the 12 months pre-index stay (pre-MAW), patients whose first MAW claim occurred during or within the 12 months after the index stay (post-MAW), or patients without any MAW claim (no-MAW). Demographics and comorbidities during 1 year prior to the index stay, and health care utilization and costs during 1 year before and after the index stay were compared among groups. Multivariate regressions were performed to estimate 1-year post-index medical costs controlling for cross-cohort differences. RESULTS: There were 23,127 commercially-insured (pre-MAW: 323; post-MAW: 1,176; no-MAW: 21,628) and 19,607 Medicare (pre-MAW: 332; post-MAW: 909; no-MAW: 18,366) patients identified. Compared with commercially-insured patients in the post-MAW and no-MAW cohorts, individuals in the pre-MAW cohort were more likely to have any hospitalization during the 12 months pre-index stay (33.4% vs. 12.7% vs. 10.5%; both pϽ0.05), a higher Charlson comorbidity index score (5.5 vs. 4.3 vs. 3.9; both pϽ0.05), and higher total costs ($35,022 vs. $15,011 vs. 12,952; both pϽ0.05). Controlling for crosscohort differences, both pre-MAW and post-MAW cohorts had significantly higher total health care costs ($6697 and $8593) than the no-MAW cohort (both pϽ0.01) during the 12 months post-index stay. Similar trends were observed in the Medicare population. CONCLUSIONS: Among US patients receiving THR surgery, those with MAW had higher health care costs than patients without MAW. 
PSU27 CLINICAL AND ECONOMIC CHARACTERISTICS OF PATIENTS RECEIVING TOTAL HIP REPLACEMENT SURGERY WITH AND WITHOUT MUSCLE ATROPHY/WEAKNESS
PSU28 VARIABLES ASSOCIATED WITH LENGTH OF STAY AND ICU NEED IN ROUX-EN-Y GASTRIC BYPASS SURGERY FOR MORBID OBESE PATIENTS: A CROSS-SECTIONAL STUDY BASED ON THE PUBLIC HEALTH SYSTEM DATABASE (DATASUS) IN BRAZIL
OBJECTIVES:
This is an exploratory analysis of potential variables associated with roux-en-Y gastric bypass (RYGB) surgery hospitalization resource use pattern. METHODS: Cross-sectional study based on a public database (DATASUS) records. Inclusion criteria were patients undergoing RYGB between January 2008 and June 2011. Dependent variables were length of stay and ICU need. Independent variables were: gender, age at surgery (continuous or categorized as older/younger than 60), hospital volume (high volume: Ͼ100 RYGB/year; low volume: Յ100 RYGB/year), surgery at certified center of excellence (CoE) by the American Society for Metabolic and Bariatric Surgery (ASMBS) (yes/no), year of hospitalization. Univariate and multivariate analysis (logistic regression for ICU need and linear regression for length of stay) were performed. RESULTS: Data from 13,069 surgeries were analyzed. 14.8% of patients were male, mean age 38.2Ϯ10.4 years, 52.2% undergone surgery in a high volume hospital, 11.6% from a certified CoE by ASMBS. In the univariate analysis of potential factors associated with outcomes of interest, the variable with highest effect size for length of stay was hospital volume (high volume 3.8Ϯ1.8 days vs 6.3Ϯ7.6 low volume, pϽ0.001), whereas for ICU need it was certified CoE (50.0% vs. 1.3%, pϽ0.001). Final model for ICU need after logistic regression includes certified CoE (OR 0.009, hospital volume (OR 3.16, ) and age group (OR 1.93, CI95% 1.46-2.57). The most important variable in the final model for log-transformed length of stay is hospital volume (adjusted coefficient -0.338, CI95% -0.379 to -0.297); association was also found for certified CoE, gender and age. In high volume hospitals, variance of RYGB length of stay is significantly lower than variance in low volume hospitals (SD 2.1 vs. 11.0, pϽ0.001). CONCLUSIONS: High volume hospitals are strongly associated with shorter length of stay and less variability, and ASMBS certification is strongly associated with less need for ICU. 
SURGERY -Patient-Reported Outcomes & Patient Preference Studies
PSU29 THE IMPORTANCE OF MEDICAL APPOINTMENTS AFTER ROUX-EN-Y GASTRIC BYPASS IN MORBID OBESE PATIENTS: ASSOCIATION BETWEEN ADHERENCE TO MEDICAL FOLLOW-UP VISITS AND THE BARIATRIC ANALYSIS AND REPORTING OUTCOME SYSTEM (BAROS) SCORE BASED ON AN ADMINISTRATIVE DATABASE (DATASUS) IN BRAZIL
OBJECTIVES:
Correct clinical management of morbid obese patients does not begin and neither ends with bariatric surgery. The aim of this study was to evaluate the association between number of medical follow-up visits after surgery and patient outcomes in morbid obese patients undergoing roux-en-Y gastric bypass (RYGB). METHODS: This is a database (DATASUS) retrospective cohort study. Inclusion criteria was patients undergoing RYGB between January 2008 and June 2010 with at least one medical follow-up visit. The dependent variable was the Bariatric Analysis and Reporting Outcome System (BAROS) score, which combines clinical (%Ex-cess weight loss, co-morbidity resolution) and quality of life outcomes in one categorical variable (failure/fair/good/very good/excellent). Independent variable was adherence to medical follow-up visits, adjusted for potential covariates. Univariate and multivariate analysis (by linear regression) were performed at 12 and 24
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